Skip to search formSkip to main contentSkip to account menu

Allogeneic Conditioning

Known as: Allo Conditioning, Allogeneic (allo) Conditioning 
A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Excretion of Ascaris lumbricoides following reduced‐intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole
Here, we present the unique case of a 51‐year‐old German patient with multiple myeloma excreting Ascaris lumbricoides in his… 
2016
2016
Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan (90YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies
Background: Nonmyeloablative allogeneic transplantation has the potential to induce long-term remissions in patients with… 
2011
2011
Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd
Abstract 894 Background: We previously reported the use of fludarabine, cyclophosphamide and rituximab as a nonmyeloablative… 
Review
2010
Review
2010
Complete donor T‐cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high‐risk chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is often indolent, however some patients will demonstrate an aggressive disease course. Over… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)